Hims & Hers Health announced a definitive agreement to acquire Eucalyptus, Australia's premier digital healthcare platform, for up to $1.15 billion USD. The deal includes $240 million in cash at closing, with deferred payments and earnout provisions extending through 2029. Eucalyptus operates in Australia, the UK, Germany, with expanding operations in Japan and Canada.

The acquisition represents strategic diversification for Hims & Hers amid regulatory challenges in the US, where the company was forced to withdraw its $49 compounded oral semaglutide pill following FDA crackdown and referral to the Department of Justice. Eucalyptus brings an annual revenue run-rate exceeding $450 million and more than 775,000 customers. The Australian company's portfolio includes weight-loss platform Juniper, men's health service Pilot, and fertility brand Kin.

This transaction represents one of the most significant consolidations in telehealth industry history, signaling a decisive shift toward unified global consumer health ecosystems. The acquisition is expected to close mid-2026 following regulatory approvals. For APAC's investment landscape, the deal demonstrates growing appetite for healthcare infrastructure assets, particularly as regional digital health adoption accelerates post-pandemic.

The Eucalyptus cap table includes local funds Blackbird, Airtree, Woolworths VC fund W23, OneVentures, Athletic Ventures, alongside US investor Mary Meeker's BOND Capital. The startup more than tripled its $520 million valuation from April 2023, delivering substantial returns to early Australian backers. Co-founder Tim Doyle is set to bank around $160 million from the deal, becoming SVP of International at the combined entity.

Australia's Largest Telehealth Exit Delivers $1.15B to Local VCs

India maintained strong momentum with 457 deals worth US$13.7 billion in H1 2025, supported by stable regulatory environment and expanding tech opportunities. The Eucalyptus valuation multiple suggests India's largest digital health platforms, with their massive addressable markets and demonstrated unit economics, could command similar premiums from international strategic buyers seeking emerging market exposure.

India's Digital Health Scale Could Drive Mega-Deals

The Eucalyptus premium suggests Singapore's mature digital health platforms could attract similar strategic interest from global acquirers. With Singapore serving as regional headquarters for many international healthcare companies, local telehealth platforms with proven regulatory frameworks and multi-market operations present compelling acquisition targets for US and European consolidators seeking APAC market entry.

Singapore Healthcare VCs Eye Similar Consolidation Plays

hims-and-hers-health

eucalyptus

australia

germany

japan

canada

juniper

pilot

How Hims & Hers' acquisition of Australia's largest telehealth platform reshapes APAC's healthcare investment landscape.

$1.15B Eucalyptus buyout transforms APAC digital health

Hims & Hers' mega-deal marks largest digital health consolidation in APAC history.

Signs emerge that Asia Pacific is producing companies attracting strategic capital at different orders of magnitude once they cross into infrastructure zones. The Eucalyptus acquisition follows broader APAC trends where healthcare platforms achieve premium valuations through proven operational scale and regulatory compliance.

The region is moving according to different logic, shaped by state influence, institutional coordination, fragmented healthcare delivery, and extraordinary demographic pressure. This creates unique opportunities for healthcare consolidation as platforms seek geographic expansion and regulatory arbitrage across diverse APAC markets.

Eucalyptus deal signals shift from venture to strategic acquisitions across region.

APAC Healthcare Infrastructure Attracts Record Strategic Capital

US Telehealth Giant Acquires Australia's Eucalyptus for $1.15 Billion

US telehealth company Hims & Hers Health announced a definitive agreement to acquire Australian digital health leader Eucalyptus for up to $1.15 billion, marking the largest digital health acquisition in Australia's history. The deal, expected to close in mid-2026, will see $240 million paid in cash at closing, with the remainder structured as deferred payments and performance-based earnouts.

Eucalyptus operates multiple consumer healthcare brands including Juniper and Pilot, serving over 775,000 customers across Australia, UK, Germany, Japan and Canada with an annual revenue run-rate exceeding $450 million USD. The acquisition has caught attention across Australia's digital health sector, demonstrating premium valuations for high-growth telehealth platforms, with industry experts noting the deal represents a mid-to-high single-digit historic revenue multiple.

The acquisition enables Hims & Hers' expansion into Australia and Japan while deepening its presence in the UK, Germany and Canada. Following completion, Eucalyptus CEO Tim Doyle will become SVP of International at Hims & Hers, overseeing all international operations. The deal signals significant consolidation in global telehealth and positions Hims & Hers as a leading international consumer health platform.

The $1.15 billion Eucalyptus acquisition represents by far the largest acquisition of a preventative healthcare company in Australia, delivering a sizeable payday for founder Tim Doyle and private equity backers. The deal valuation implies a premium multiple at the upper end of prevailing sector benchmarks.

Eucalyptus was the first Australian telehealth business to receive accreditation from the Australian Council on Healthcare Standards and has published over 20 peer-reviewed studies examining patient outcomes, adherence and safety. The acquisition validates Australia's position as a leading digital health innovation hub.

Australia Sees Largest Digital Health Exit

Recent Singapore investment activity in Australian healthcare includes the $40 million rescue of Seer Medical by Cadwell Industries, Breakthrough Victoria and TrialCap Pte Ltd. Cadwell will integrate Seer's EEG technology into its global neurodiagnostic portfolio, demonstrating continued cross-border healthcare technology interest between the two markets.

Singapore Investors Eye Australian Digital Health

hims-hers

US telehealth giant completes Australia's largest digital health acquisition.

The Eucalyptus acquisition represents one of the most significant consolidations in global telehealth history, turning Hims & Hers into an international powerhouse. This follows broader APAC digital health trends, with strategic deals totalling $2.65 billion in Q1 2026 versus just $244 million in traditional VC funding, highlighting the sector's shift toward infrastructure-led capital.

Industry analysts expect the deal to put Australia's preventative healthcare sector on the radar of both domestic and international buyers. Recent cross-border M&A activity has been relatively small but notably involves overseas acquirers targeting Australian digital health assets, suggesting increased international interest in the region's mature telehealth market.

Major US acquisition signals new era for regional telehealth market.

APAC Digital Health Consolidation Accelerates

Hims Hers Acquires Eucalyptus for $1.15 Billion

Hims & Hers Health (NYSE: HIMS) announced on February 19 its definitive agreement to acquire Eucalyptus, Australia's premier digital healthcare platform, for up to $1.15 billion. The deal, expected to close mid-2026, includes $240 million in cash upfront, with deferred and earnout payments extending through early 2029. Eucalyptus reported over $450 million in annual recurring revenue as of January 2026, having served more than 775,000 customers across Australia, UK, Germany, Japan and Canada.

The transaction represents one of the most significant consolidations in telehealth industry history, signaling a decisive shift toward a unified global consumer health ecosystem. Eucalyptus operates five digital healthcare clinics including women's weight-loss company Juniper, men's health brands Pilot and Compound, reproductive healthcare company Kin, and Software's telehealth services with clinical-grade skincare formulas. The acquisition comes as Hims & Hers faces regulatory volatility in the US following an FDA crackdown on its $49 compounded oral semaglutide pill and subsequent withdrawal.

Upon closing, Hims & Hers will expand into Australia and Japan while deepening presence in UK, Germany and Canada. The company targets over $1 billion in international annual revenue within three years. Eucalyptus CEO Tim Doyle will become SVP of International at Hims & Hers, overseeing global business operations. Regulatory approvals from Australia's Competition and Consumer Commission (ACCC) and Foreign Investment Review Board (FIRB) remain pending.

The AU$1.6 billion acquisition more than triples Eucalyptus's $520 million valuation from its April 2023 funding round, delivering massive returns to local investors including Blackbird, Airtree, Woolworths' W23 fund, OneVentures, and Athletic Ventures. Co-founder and CEO Tim Doyle is set to bank around $160 million from the deal while transitioning to lead Hims & Hers' international operations.

Founded in 2019, Eucalyptus became Australia's first telehealth provider to receive accreditation from the Australian Council on Healthcare Standards, publishing over 20 peer-reviewed studies on care model outcomes. The company operates four demographic-focused brands: Pilot (men's health), Juniper (women's weight loss and menopause), Kin (fertility), and Software (prescription skincare).

Eucalyptus Exit Delivers $1.6 Billion Value to Australian Investors

Indian health tech companies secured significant funding including Plum Benefits ($20.5M employee health insurance) and Even Healthcare ($20M integrated care), reflecting continued investor conviction in the market's affordability-focused innovation. India's digital health market brings intensity of demand and constant pressure on affordability, creating unique innovation dynamics compared to other APAC markets.

India maintained strong private equity momentum with 457 deals worth $13.7 billion in H1 2025, representing 21 percent of regional activity, supported by stable regulatory environment, strong demographics and expanding tech and infrastructure opportunities. China and India are identified as regional bright spots for rapid tech and AI expansion, particularly in healthcare infrastructure development.

India's Health Tech Sector Draws Strategic Investment Interest

Singapore's Temasek Holdings participated in a consortium that invested A$100 million in Australian plastic recycling firm Samsara Eco, while other Singapore entities including Cyan Renewables acquired MMA Offshore for A$1.1 billion. Singapore's Monetary Authority frameworks like the Long-Term Investment Fund (LIF) are opening pathways for private credit expansion across the region.

Southeast Asia markets including Singapore remain highly active in fintech space, with the city-state serving as a key hub for cross-border investment activity. Singapore accounted for 50 percent of Southeast Asian private equity activity despite regional slowdown to $3.6 billion in H1 2025.

Singapore Hub Benefits from Cross-Border Health Tech Flows

compound

software

accc

firb

US telehealth giant targets APAC expansion with Australia's largest digital health platform.

The $1.15 billion transaction consolidates Australia's largest direct-to-consumer telehealth platform into a US-listed global operator. APAC digital health funding reached $2.65 billion in strategic deals versus just $244 million in traditional VC funding during Q1 2026, with Australian companies like Splose ($32M Series A2), Lumonus ($20M), and Omniscient Neurotechnology ($20M) securing significant rounds.

Private equity momentum continues across APAC, with India recording 457 deals worth $13.7 billion in H1 2025, while Southeast Asia activity reached $3.6 billion despite trade tensions shifting production to Vietnam, Indonesia and Thailand. Japan and Australia have seen rapid private equity growth in technology sectors, particularly data centers supporting AI expansion, with J.P. Morgan committing an additional $50 billion to direct lending, some targeting APAC markets.

Arc Brief

Eucalyptus

News Coverage

US Telehealth Giant Acquires Australia's Eucalyptus for $1.15 Billion

Hims Hers Acquires Eucalyptus for $1.15 Billion

Hims & Hers Acquires Australia's Eucalyptus for $1.15 Billion